24/7 Market News Snapshot 13 January, 2025 – bioAffinity Technologies, Inc. Common Stock (NASDAQ:BIAF)

January 13, 2025

DENVER, Colo., 13 January, 2025 (247marketnews.com) – (NASDAQ:BIAF) are discussed in this article.
bioAffinity Technologies, Inc. (BIAF) is currently experiencing a notable rise in its stock price, trading at $0.892, which represents a substantial increase of 10.12% from its previous close of $0.810. This uptick is buoyed by impressive trading volume, reaching 2.01 million shares, signaling a strong interest from investors. Technical analyses indicate the possibility of an upward breakout, with resistance levels potentially forming around $0.90, suggesting traders should pay close attention to volume patterns and price movements.

In tandem with its market performance, bioAffinity Technologies announces significant advancements in its pioneering CyPath® Lung pilot program for early-stage cancer diagnostics. In 2024 alone, the company has delivered over 600 tests, reflecting an increasing embrace of innovative diagnostic solutions aimed at enhancing patient care. Maria Zannes, the President and CEO, highlighted the remarkable progress made, with a growing number of physicians and pulmonary practices adopting CyPath® Lung within their diagnostic offerings. The company is set to expand its sales efforts to veteran and military medical systems, further broadening its reach.

The performance of CyPath® Lung has been remarkable, achieving clinical accuracy with a sensitivity of 92% and specificity of 87% in high-risk patients. Its capability to identify various lung cancer subtypes positions the test as a critical tool for early detection and timely intervention. A peer-reviewed economic study led by distinguished pulmonologists has indicated that the adoption of CyPath® Lung could generate significant healthcare savings, estimating cost reductions of over $895 million.

As bioAffinity Technologies prepares to enhance its marketing initiatives in 2025 in collaboration with key opinion leaders, the company remains committed to transforming early lung cancer detection, promising improved outcomes and peace of mind for at-risk patients.

Related news for (BIAF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.